A meta-analysis was conducted to examine the influence of SGLT2 inhibitors on heart failure outcomes and cardiovascular mortality across diverse patient populations and found that SGLT2 inhibitors have been shown to decrease the risk of heart failure events and cardiovascular death in patient populations with heart failure, diabetes mellitus type II, and CKD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.